Challenging Treatment of Ocular Surface Squamous Neoplasia in Patients with Atopic Disease

ABSTRACT

Purpose: Few studies have described ocular surface squamous neoplasia (OSSN) and its association with atopic diseases and there is no consensus on the course of OSSN in atopic patients. We thereby report three patients with atopy and OSSN.

Methods: Retrospective case series.

Results: Three male patients with mean age of 73 presented with OSSN and history of atopy treated with immunosuppressant therapy. Their histories included atopic dermatitis and keratoconjunctivitis. All patients had treatment complicated by multiple surgeries, recurrences, or advanced disease. The patients initially received medical treatment with topical interferon-alpha-2b (IFNα2b). However, all the patients had recurrences and required modification of treatment including topical 5-fluorouracil (5-FU).

Conclusion: We report on three patients with a history of atopy whose OSSN presentation and course was challenging. Overall, our cases responded better to topical 5-fluorouracil compared to topical interferon-alpha-2b, but recurrences were common. These patients may benefit from more aggressive and long-term treatment.

Keywords:

• Atopy
• ocular surface squamous neoplasia
• OSSN
• atopic disease
• 5- fluorouracil
• interferon-alpha-2b

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Funding

Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S (Dr. Galor), NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, The Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy and Gaye Bryan Grant, The H. Scott Huizenga Grant, The Robert Baer Family Grant, The Gordon Charitable Foundation, Emilyn Page and Mark Feldberg Grant, and the Richard Azar Family Grant (institutional grants).

Additional information

Funding

Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S (Dr. Galor), NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, The Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy and Gaye Bryan Grant, The H. Scott Huizenga Grant, The Robert Baer Family Grant, The Gordon Charitable Foundation, Emilyn Page and Mark Feldberg Grant, and the Richard Azar Family Grant(institutional grants);The Jimmy and Gaye Bryan Grant;The Robert Baer Family Grant;Richard and Kathy Lesser Grant;The Richard Azar Family Grant;The Lee and Claire Hager Grant;